In a previous large-scale study examining the benefits of erlotinib treatment for NSCLC, analysis of EGFR mutations using cytology specimens was possible in only 197 of 731 (27%) patients (Tsao et al, 2005). This evidence concerns the gene EGFR and non-small cell lung carcinoma.